

Antigen-antibody interaction

From Wikipedia, the free encyclopedia

[Jump to navigation](#) [Jump to search](#)

Antigen-antibody interaction, or **antigen-antibody reaction**, is a specific chemical interaction between [antibodies](#) produced by [B cells](#) of the [white blood cells](#) and [antigens](#) during [immune reaction](#). The antigens and antibodies combine by a process called agglutination. It is the fundamental reaction in the body by which the body is protected from complex foreign molecules, such as pathogens and their chemical toxins. In the blood, the antigens are specifically and with high affinity bound by antibodies to form an antigen-antibody complex. The immune complex is then transported to cellular systems where it can be destroyed or deactivated.

The first correct description of the antigen-antibody reaction was given by Richard J. Goldberg at the [University of Wisconsin](#) in 1952.^{[1][2]} It came to be known as "Goldberg's theory" (of antigen-antibody reaction).^[3]

There are several types of antibodies and antigens, and each antibody is capable of binding only to a specific antigen. The specificity of the binding is due to specific chemical constitution of each antibody. The [antigenic determinant](#) or epitope is recognized by the [paratope](#) of the antibody, situated at the variable region of the polypeptide chain. The variable region in turn has hyper-variable regions which are unique [amino acid sequences](#) in each antibody. Antigens are bound to antibodies through weak and noncovalent interactions such as [electrostatic interactions](#), [hydrogen bonds](#), [Van der Waals forces](#), and [hydrophobic interactions](#).^[4]

The principles of specificity and cross-reactivity of the antigen-antibody interaction are useful in clinical laboratory for diagnostic purposes. One basic application is determination of ABO blood group. It is also used as a molecular technique for infection with different pathogens, such as HIV, microbes, and helminth parasites.

Contents


- [1 Molecular basis](#)
 - [1.1 Antibody structure](#)
- [2 Properties](#)
 - [2.1 Chemical basis of antigen-antibody interaction](#)
 - [2.2 Affinity of the interaction](#)
- [3 Auto immune disease](#)
- [4 Application](#)

- [4.1 Precipitation reaction](#)
- [4.2 Agglutination reaction](#)
- [5 References](#)
- [6 External links](#)

Molecular basis[[edit](#)]


Immunity developed as an individual is exposed to antigens is called adaptive or acquired immunity, in contrast to immunity developed at birth, which is innate immunity. Acquired immunity depends upon the interaction between antigens and a group of proteins called antibodies produced by B cells of the blood. There are many antibodies and each is specific for a particular type of antigen. Thus immune response in acquired immunity is due to the precise binding of antigens to antibody. Only very small area of the antigens and antibody molecules actually interact through complementary binding sites, called epitopes in antigens and paratopes in antibody.^[5]

Antibody structure[[edit](#)]



Structural model of an antibody molecule. Rounded portions indicate antigen binding sites.

In an antibody, the [Fab \(fragment, antigen-binding\) region](#) is formed from the amino-terminal end of both the light and heavy chains of the [immunoglobulin](#) polypeptide. This region, called the variable (V) domain, is composed of amino acid sequences that define each type of antibody and their binding affinity to an antigen. The combined sequence of variable light chain (V_L) and variable heavy chain (V_H) creates three hypervariable regions (HV1, HV2, and HV3). In V_L these are roughly from residues 28 to 35, from 49 to 59, and from 92 to 103, respectively. HV3 is the most variable part. Thus these regions may be part of a paratope, the part of an antibody that recognizes and binds to an antigen. The rest of the V region between the hypervariable regions are called framework regions. Each V domain has four framework domains, namely FR1, FR2, FR3, and FR4.^{[4][6]}



Structure of hen egg lysozyme (HEL) antigen. (A) The 3-D structure of HEL (CPK representation) together with three Abs (ribbon representation). (B) The structure of HEL colored according to the same three epitopes as in (A). (C) The structure of HEL colored according to the epitopes predicted by Discotope (light blue), ellipro (purple), and seppa (pink).

Properties[[edit](#)]

Chemical basis of antigen-antibody interaction[[edit](#)]

Antibodies bind antigens through weak chemical interactions, and bonding is essentially [non-covalent](#). [Electrostatic interactions](#), [hydrogen bonds](#), [van der Waals forces](#), and [hydrophobic interactions](#) are all known to be involved depending on the interaction sites.^{[7][8]} Non-covalent bonds between antibody and antigen can also be mediated by interfacial water molecules. Such indirect bonds can contribute to the phenomenon of cross-reactivity, i.e. the recognition of different but related antigens by a single antibody.^[9]

Affinity of the interaction[[edit](#)]

Antigen and antibody interact through a high affinity binding much like lock and key.^[10] A dynamic equilibrium exists for the binding. For example, the reaction is a reversible one, and can be expressed as:

where $[Ab]$ is the [antibody](#) concentration and $[Ag]$ is the [antigen](#) concentration, either in free ($[Ab],[Ag]$) or bound ($[AbAg]$) state.

The equilibrium association constant can therefore be represented as:

where K is the [equilibrium constant](#).

Reciprocally the dissociation constant will be:

However, these equations are applicable only to a single epitope binding, i.e. one antigen on one antibody. Since the antibody necessarily has two paratopes, and in many circumstances complex binding occurs, the multiple binding equilibrium can be summed up as:

where, at equilibrium, c is the concentration of free ligand, r represents the ratio of the concentration of bound ligand to total antibody concentration and n is the maximum number of binding sites per antibody molecule (the antibody valence).

The overall strength of the binding of an antibody to an antigen is termed its [avidity](#) for that antigen. Since antibodies are bivalent or polyvalent, this is the sum of the strengths of individual antibody-antigen interactions. The strength of an individual interaction between a single binding site on an antibody and its target epitope is termed the affinity of that interaction.

Avidity and affinity can be judged by the [dissociation constant](#) for the interactions they describe. The lower the dissociation constant, the higher the avidity or affinity, and the stronger the interaction.

Auto immune disease[\[edit\]](#)

Normally antibodies can detect and differentiate molecules from outside of the body and those produced inside the body as a result of cellular activities. Self molecules are ignored by the immune system. However, in certain conditions, the antibodies recognise self molecules as antigens and triggers unexpected immune responses. This results in different autoimmune diseases depending on the type of antigens and antibodies involved. Such conditions are always harmful and sometimes deadly. The exact nature of antibody-antigen interaction in autoimmune disease is not yet understood.^{[11][12]}

Application[\[edit\]](#)

Antigen-antibody interaction is used in laboratory techniques for serological test of blood compatibility and various pathogenic infections. The most basic is ABO blood group determination, which is useful for blood transfusion.^[13] Sophisticated

applications include [ELISA](#),^[14] enzyme-linked immunospot (Elispot), immunofluorescence, and immunoelectrophoresis.^{[15][16][17]}

Precipitation reaction[\[edit\]](#)

Soluble antigens combine with soluble antibodies in presence of an electrolyte at suitable temperature and pH to form insoluble visible complex. This is called a precipitation reaction. It is used for qualitative and quantitative determination of both antigen and antibody. It involves the reaction of soluble antigen with soluble antibodies to form large interlocking aggravated called lattice. It occurs in two distinct stages. Firstly, the antigen and antibody rapidly form antigen-antibody complexes within few seconds and this is followed by a slower reaction in which the antibody-antigen complexes forms lattices that precipitate from the solution.

A special ring test is useful for diagnosis of anthrax and determination of adulteration in food.

Agglutination reaction[\[edit\]](#)

It acts on antigen-antibody reaction in which the antibodies cross-link particulate antigens resulting in the visible clumping of the particle. There are two types, namely active and passive agglutination. They are used in blood tests for diagnosis of enteric fever.

References[\[edit\]](#)

1. [^] [Goldberg, Richard J. \(1952\). "A Theory of Antibody—Antigen Reactions. I. Theory for Reactions of Multivalent Antigen with Bivalent and Univalent Antibody". *Journal of the American Chemical Society*. **74** \(22\): 5715–5725. *doi*:\[10.1021/ja01142a045\]\(#\).](#)
2. [^] [Sahimi, Muhammad \(1994\). *Applications of Percolation Theory*. London: CRC Press. p. 257. *ISBN* \[978-0-203-22153-2\]\(#\).](#)
3. [^] [Spiers, JA \(1958\). "*Goldberg's theory of antigen-antibody reactions in vitro*". *Immunology*. **1** \(2\): 89–102. *PMC* \[1423897\]\(#\). *PMID* \[13538526\]\(#\).](#)
4. [^] [Jump up to:^a ^b Janeway, Charles A Jr; Travers, Paul; Walport, Mark; Shlomchik, Mark J \(2001\). *Immunobiology: The Immune System in Health and Disease* \(5 ed.\). New York: Garland Science. *ISBN* \[0-8153-3642-X\]\(#\).](#)
5. [^] [Sela-Culang, Inbal; Kunik, Vered; Ofran, Yanay \(2013\). "*The structural basis of antibody-antigen recognition*". *Frontiers in Immunology*. **4**: 302. *doi*:\[10.3389/fimmu.2013.00302\]\(#\). *PMC* \[3792396\]\(#\). *PMID* \[24115948\]\(#\).](#)
6. [^] [Mian, I.Saira; Bradwell, Arthur R.; Olson, Arthur J. \(1991\). "Structure, function and properties of antibody binding sites". *Journal of Molecular Biology*. **217** \(1\): 133–151. *doi*:\[10.1016/0022-2836\\(91\\)90617-F\]\(#\). *PMID* \[1988675\]\(#\).](#)

7. [^] [van Oss, CJ; Good, RJ; Chaudhury, MK \(1986\)](#). "Nature of the antigen-antibody interaction. Primary and secondary bonds: optimal conditions for association and dissociation". *Journal of Chromatography*. **376**: 111–9. [PMID 3711190](#).
8. [^] [Absolom, DR; van Oss, CJ \(1986\)](#). "The nature of the antigen-antibody bond and the factors affecting its association and dissociation". *CRC Critical Reviews in Immunology*. **6** (1): 1–46. [PMID 3522103](#).
9. [^] [Lisova, O; Belkadi, L; Bedouelle, Hugues \(Apr 2014\)](#). "Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus". *J. Mol. Recognit.* **27** (4): 205–214. [doi:10.1002/jmr.2352](#). [PMID 24591178](#).
10. [^] [Braden, BC; Dall'Acqua, W; Eisenstein, E; Fields, BA; Goldbaum, FA; Malchiodi, EL; Mariuzza, RA; Schwarz, FP; Ysern, X; Poljak, RJ \(1995\)](#). "Protein motion and lock and key complementarity in antigen-antibody reactions". *Pharmaceutica Acta Helveticae*. **69** (4): 225–30. [doi:10.1016/0031-6865\(94\)00046-x](#). [PMID 7651966](#).
11. [^] [Cornaby, Caleb; Gibbons, Lauren; Mayhew, Vera; Sloan, Chad S.; Welling, Andrew; Poole, Brian D. \(2015\)](#). "B cell epitope spreading: Mechanisms and contribution to autoimmune diseases". *Immunology Letters*. **163** (1): 56–68. [doi:10.1016/j.imlet.2014.11.001](#). [PMID 25445494](#).
12. [^] [Imkeller, Katharina; Wardemann, Hedda \(2018\)](#). "[Assessing human B cell repertoire diversity and convergence](#)". *Immunological Reviews*. **284** (1): 51–66. [doi:10.1111/imr.12670](#). [PMID 29944762](#).
13. [^] [Mayer, Gene](#). "[Immunoglobulins- antigen-antibody reactions and selected tests](#)". *Microbiology and Immunology*. University of South Carolina School of Medicine. Retrieved 10 March 2015.
14. [^] [Margolis, Simeon \(5 January 2012\)](#). "[Antigen/Antibody Tests for Infectious Disease](#)". *Remedy Health Media, LLC*. Retrieved 10 March 2015.
15. [^] [Taylor, Charles W.; Chakrabarty, Subhas; Schauder, Keith S.; Yeoman, Lynn C. \(1983\)](#). "Identification of Cytosolic Antigens from GW-39 Adenocarcinoma Cells by Crossed Immunoelectrophoresis and Immunofluorescence". *Immunological Investigations*. **12** (3): 315–329. [doi:10.3109/08820138309050753](#).
16. [^] [Ferenčik, Miroslav \(2013\)](#). *Handbook of Immunochemistry*. Netherlands: Springer. pp. 309–386. [doi:10.1007/978-94-011-1552-0_12](#). [ISBN 978-94-010-4678-7](#).
17. [^] [Odell, Ian D; Cook, Deborah \(2013\)](#). "[Immunofluorescence Techniques](#)". *Journal of Investigative Dermatology*. **133** (1): e4. [doi:10.1038/jid.2012.455](#). [PMID 23299451](#).

External links[[edit](#)]

- [Antigen-antibody reaction](#)
- [Discover Biotech](#)

Retrieved from "https://en.wikipedia.org/w/index.php?title=Antigen-antibody_interaction&oldid=1013372062"

[Categories:](#)

- [Immunology](#)
- [Immune system](#)
- [Hematology](#)

Navigation menu

Personal tools

- Not logged in
- [Talk](#)
- [Contributions](#)
- [Create account](#)
- [Log in](#)

Namespaces

- [Article](#)
- [Talk](#)



Variants

Views

- [Read](#)
- [Edit](#)
- [View history](#)



More

Search

<input type="text" value="Search"/>	<input type="button" value="Go"/>
-------------------------------------	-----------------------------------

Navigation

- [Main page](#)
- [Contents](#)

- [Current events](#)
- [Random article](#)
- [About Wikipedia](#)
- [Contact us](#)
- [Donate](#)

Contribute

- [Help](#)
- [Learn to edit](#)
- [Community portal](#)
- [Recent changes](#)
- [Upload file](#)

Tools

- [What links here](#)
- [Related changes](#)
- [Upload file](#)
- [Special pages](#)
- [Permanent link](#)
- [Page information](#)
- [Cite this page](#)
- [Wikidata item](#)

Print/export

- [Download as PDF](#)
- [Printable version](#)

Languages

- [العربية](#)
- [Español](#)
- [한국어](#)
- [Bahasa Indonesia](#)
- [日本語](#)
- [Српски / srpski](#)

[Edit links](#)

- This page was last edited on 21 March 2021, at 08:01 (UTC).

- Text is available under the [Creative Commons Attribution-ShareAlike License](#); additional terms may apply. By using this site, you agree to the [Terms of Use](#) and [Privacy Policy](#). Wikipedia® is a registered trademark of the [Wikimedia Foundation, Inc.](#), a non-profit organization.

- [Privacy policy](#)
- [About Wikipedia](#)
- [Disclaimers](#)
- [Contact Wikipedia](#)
- [Mobile view](#)
- [Developers](#)
- [Statistics](#)
- [Cookie statement](#)

